Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy
Protocol ID
ALLELE (ATA129-EBV-302)
Disease (Sub Disease)
EBV post transplant
Diagnosis Stage
Refractory
Location
NSW, VIC, WA
Sponsor
Atara Biotherapeutics
Links
Trial Status
Open
Sites
Perth Children's Hospital
Royal Children's Hospital
The Children's Hospital at Westmead
Royal Children's Hospital
The Children's Hospital at Westmead
Study Type
Treatment
Phase
Phase 3
Age Eligibility
no limits
International registry ID's
NCT03394365
| Study Title | Multicenter Open Label Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy |
|---|---|
| Protocol ID | ALLELE (ATA129-EBV-302) |
| Disease (Sub Disease) | EBV post transplant |
| Diagnosis Stage | Refractory |
| Location | NSW / VIC / WA |
| Sponsor | Atara Biotherapeutics |
| Links | https://clinicaltrials.gov/ct2/show/NCT03394365 |
| Trial Status | Open |
| Trial Open Date | 29/12/2017 |
| Sites | Perth Children's Hospital / Royal Children's Hospital / The Children's Hospital at Westmead |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | no limits |
| International registry ID's | NCT03394365 |